This is a preview of subscription content, log in via an institution to check access.
Notes
from France, Germany, Italy, Spain and the UK
Reference
Decision Resources. Surveyed EU5 Oncologists Plan Increased Uptake of Perjeta for HER2-Positive Breast Cancer, But Expect Reimbursement Hurdles for Perjeta Plus Kadcycla. Media Release : 7 Nov 2013. Available from: URL: http://www.decisionresources.com
Rights and permissions
About this article
Cite this article
High costs may limit uptake of some HER2-targeted treatments. PharmacoEcon Outcomes News 691, 10 (2013). https://doi.org/10.1007/s40274-013-0877-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0877-5